Business Context and Reporting Period
This Form 8-K Current Report was filed by Acadia Pharmaceuticals Inc. on March 3, 2026. The filing discloses a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on director compensation arrangements.
Material Changes
The primary material change reported is the appointment of Jonathan M. Poole to the Board of Directors and the Audit Committee, effective immediately. This appointment fills a vacancy on the Board.
Management Commentary and Compensation Details
Mr. Poole's compensation package includes the following components:
- Cash Retainers: An annual cash retainer of $50,000 for Board service and $12,500 for Audit Committee service, prorated and payable per policy.
- Initial Equity Grant: An aggregate target fair value of $200,000, split equally between nonstatutory stock options and restricted stock units (RSUs). These vest in equal annual installments over three years.
- Prorated Annual Grant: An aggregate target fair value of $95,300, split equally between options and RSUs. Options vest quarterly over one year; RSUs vest in full upon the earlier of one year or the next annual meeting.
- Future Annual Grants: Commencing with the 2026 Annual Meeting, Mr. Poole is eligible for annual grants with a target fair value of $400,000, split equally between options and RSUs.
Mr. Poole has entered into the Company's standard indemnification agreement. No related person transactions requiring disclosure under Item 404(a) of Regulation S-K were identified.
Investor Verification Checklist
- Verify the total number of shares underlying the equity grants based on the current stock price and the stated fair values.
- Review the full text of the 2024 Equity Incentive Plan to understand specific vesting conditions and "Continuous Service" definitions.
- Confirm the impact of the new director appointment on the composition of the Audit Committee.
- Check for any subsequent filings regarding the vesting schedule or changes to the Non-Employee Director Compensation Policy.